Literature DB >> 15517447

Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha.

Meral Calgüneri1, Ahmet Mesut Onat, M Akif Oztürk, Levent Ozçakar, Kemal Ureten, Ali Akdogan, Ihsan Ertenli, Sedat Kiraz.   

Abstract

We report here on a 24-year-old patient with Behcet's disease who had been diagnosed with acute transverse myelitis. He was successfully treated with a combination regimen of a steroids, cyclophosphamide, and interferon-alpha. The treatment strategy with specific emphasis on interferon-alpha is discussed in the light of the pertinent literature.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15517447     DOI： 10.1007/s10067-004-0944-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  18 in total

1.  Neurological complications in Behçet's syndrome.

Authors:  D Kidd; A Steuer; A M Denman; P Rudge
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

2.  Treatment of Adamantiades-Behçet disease with systemic interferon alfa.

Authors:  C C Zouboulis; C E Orfanos
Journal:  Arch Dermatol       Date:  1998-08

3.  Seven-year follow-up of neurologic involvement in Behçet syndrome.

Authors:  G Akman-Demir; B Baykan-Kurt; P Serdaroglu; H Gürvit; S Yurdakul; H Yazici; S Bahar; E Aktin
Journal:  Arch Neurol       Date:  1996-07

4.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

5.  Systemic interferon alpha 2b treatment in Behçet's syndrome.

Authors:  V Hamuryudan; F Moral; S Yurdakul; C Mat; Y Tüzün; Y Ozyazgan; H Direskeneli; T Akoglu; H Yazici
Journal:  J Rheumatol       Date:  1994-06       Impact factor: 4.666

6.  [Neurological manifestations in Behcet's disease. Forty observations in a cohort of 300 patients].

Authors:  C Ben Taarit; S Turki; H Ben Maïz
Journal:  J Mal Vasc       Date:  2002-04

7.  Interferon alpha for ocular Behçet's disease.

Authors:  P Pivetti-Pezzi; M Accorinti; M P Pirraglia; R Priori; G Valesini
Journal:  Acta Ophthalmol Scand       Date:  1997-12

Review 8.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

9.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Interferon therapy for Behçet's disease.

Authors:  E Alpsoy; E Yilmaz; E Başaran
Journal:  J Am Acad Dermatol       Date:  1994-10       Impact factor: 11.527
View more
  5 in total

1.  Behçet's Disease.

Authors:  Gulsen Akman-Demir; Sabahattin Saip; Aksel Siva
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

3.  Behcet's disease presenting with sudden-onset paraplegia due to anterior spinal artery involvement: 1-year follow-up of rehabilitation in conjunction with medication.

Authors:  Iltekin Duman; Umut Guzelkucuk; Kutay Tezel; Koray Aydemir; Bilge Yılmaz
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

4.  Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet's Syndrome with refractory vascular or neurological involvement: a case series.

Authors:  Luxi Sun; Yunxia Hou; Lifan Zhang; JinJing Liu; Lu Li; Zhimian Wang; Xin Yu; Menghao Zhang; Xiaoqing Liu; Yan Zhao; Wenjie Zheng
Journal:  Ther Adv Chronic Dis       Date:  2022-07-26       Impact factor: 4.970

Review 5.  Vasculitis: From Target Molecules to Novel Therapeutic Approaches.

Authors:  Sang-Wan Chung
Journal:  Biomedicines       Date:  2021-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.